GREENFIELD, Ind., April 17, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco ...

New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members. Ms. Turner brings significant global experience in both the animal health and broader healthc ...

GREENFIELD, Ind., March 4, 2024 /PRNewswire/ -- Elanco Animal Health (NYSE: ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary. O'Neill will be responsible for the global strategy and operations of the Company's legal team, ethics & compliance organization and ESG efforts. "Shiv's ability to deliver strategic value to Elanco in the short term serving as our interim general counsel combined with her robust experience made i ...

Ancora Nominates Director Candidates Despite Elanco's Meaningful Operational Progress and Good Faith Engagement with the Investor GREENFIELD, Ind., Feb. 29, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today issued the following statement in response to the submission of four nominees to the Company's Board of Directors by Ancora Holdings Group, LLC ("Ancora"): The execution of Elanco's Innovation, Portfolio and Productivity strategy, led by CEO Jeff Simmons, is working. Elanco has re ...

Katy Grissom - Head of Investor Relations Conference Call Participants Jon Block - Stifel Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Joining me on todayÂ's call are Jeff Simmons, our President and Chief Executive Officer, Todd Young, our Chief Financial Officer, and Scott Purucker from Investor Relations. The slides referenced during this call are available on the Investor Relations section of elanco.com. TodayÂ's discussion will contain forward-looking statements. These statements are ba ...

Elanco Animal Health Incorporated (ELAN) reported $1.04 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 4.8%. EPS of $0.08 for the same period compares to $0.19 a year ago.The reported revenue represents a surprise of +3.53% over the Zacks Consensus Estimate of $999.74 million. With the consensus EPS estimate being $0.10, the EPS surprise was -20.00%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...

2023 Full Year Results 1Non-GAAP financial measures. See Appendix to this presentation for more information, including GAAP to non-GAAP reconciliations. 2Constant Currency (CC) is a non-GAAP financial measure, representing revenue growth excluding the impact of foreign exchange rates. 3Expected trade name upon approval. $76M of debt paydown in 2023 – expecting ~$300M in 2024; Announced agreement to sell aqua business for ~$1.3B in cash with net proceeds to accelerate debt paydown and deleveraging 2022 to 20 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 82-5497352 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 2500 INNOVATION WAY, GREENFIELD, INDIANA 46140 (Address an ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or kathryn.grissom@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports Fourth Quarter and Full Year 2023 Results • Fourth Quarter 2023 Financial Results: ◦ Revenue of $1,035 million ◦ Reported Net Loss of $141 million, Adjusted Net Income of $39 million ◦ Adjusted EBITDA of $165 million or 15.9% of Revenue ◦ Reported EPS of $(0.29), Adjusted EPS of $0.08 ...

Wall Street analysts forecast that Elanco Animal Health Incorporated (ELAN) will report quarterly earnings of $0.10 per share in its upcoming release, pointing to a year-over-year decline of 47.4%. It is anticipated that revenues will amount to $999.74 million, exhibiting an increase of 1.2% compared to the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.5% to its current level. This demonstrates the covering analysts' collective reassessmen ...